Rebecca J Kapolka

Title: Rebecca J Kapolka: Innovator in Antibacterial Research

Introduction

Rebecca J Kapolka is a notable inventor based in Pinellas Park, FL (US). She has made significant contributions to the field of antibacterial research, particularly through her work on N-acylated ciprofloxacin derivatives. Her innovative approach aims to combat infections caused by facultative intracellular bacteria, which are responsible for various diseases in both animals and humans.

Latest Patents

Rebecca holds a patent for her work titled "Activity of new N-acylated ciprofloxacin derivatives against facultative intracellular bacteria." This patent highlights her research on a selection of N-acyl ciprofloxacin analogues, which were chemically synthesized from ciprofloxacin. These derivatives have been tested in vitro for their antibacterial activity against several strains of facultative intracellular pathogens. Notably, seven of these derivatives, labeled RC4-125, RC4-143, RC4-147, RC5-28, RC5-29, RC5-32, and RC5-69, demonstrated significant intracellular anti-activity.

Career Highlights

Rebecca's career is marked by her dedication to advancing therapeutic development in the field of infectious diseases. Her research has the potential to lead to new treatment options for infections caused by various pathogens. She is affiliated with the University of South Florida, where she continues her innovative work.

Collaborations

Throughout her career, Rebecca has collaborated with esteemed colleagues, including Edward Turos and Burt E Anderson. These partnerships have enriched her research and contributed to the advancement of knowledge in her field.

Conclusion

Rebecca J Kapolka is a pioneering inventor whose work on N-acylated ciprofloxacin derivatives is paving the way for new therapeutic strategies against intracellular bacterial infections. Her contributions to antibacterial research are invaluable and hold promise for future medical advancements.